Clinical Trial Update: Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study [Phase 2]

View source ↗

Summary

Phase 2 TRICK study evaluating tofacitinib for refractory immune-related colitis from checkpoint inhibitor therapy; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Colitis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Khashayar Esfahani | Conditions: Immune-Mediated Colitis | Phase 2 | Status: TERMINATED